US FDA Weighs Whether Interstitial Cystitis Should Be Studied Separately From Bladder Pain

Advisory committee to vote on whether patients with interstitial cystitis, marked by Hunner's lesions, should be studied separately from the broader, more heterogeneous category of patients with bladder pain syndrome; recommendations could impact Aquinox and Urigen, which have drugs for IC/BPS in clinical development.

Seeking to move the field forward in the treatment of interstitial cystitis and bladder pain syndrome, the US FDA is asking its external advisors whether patients with these conditions should be studied together or separated into distinct groups for drug development purposes.

FDA is convening the Bone, Reproductive and Urologic Drugs Advisory Committee Dec. 7 to discuss whether bladder pain syndrome (BPS)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers